Analyst: Merck, Bristol-Myers, Roche in three-way tie for new cancer drugs
This article was originally published in Scrip
Bristol-Myers Squibb, Merck & Co. and Roche are locked in a battle to bring promising new cancer therapies to market. At a recent major medical meeting, all three made convincing arguments that their immunotherapy drugs hold great potential, but what is less clear now is which company has the leading therapy.
You may also be interested in...
Using Baxter’s Advate drug as a preventative therapy helped significantly reduce bleeding incidents in a yearlong study.
Mylan CEO Heather Bresch said she is looking to do a sizable deal that helps the US generic and specialty drug maker better compete in a consolidating field of rivals.
Biogen Idec CEO George Scangos is frank about his ambitions to dominate the market for hemophilia therapies, an opportunity he compares to the big biotech’s lead treating multiple sclerosis.